In this regard, injections of BO-112 into B16-OVA tumors resulted in increased contents CD8+ T cells recognizing TRP-2 and OVA as a surrogate tumor antigen in tumors (Fig. 5d) and in TDLN (Fig. 5e). Here, CD8A is linked to neoplasm.